Ultrafast Ionic Gelation Hemostatic Powder (AGCL): A Potential Paradigm Shift in Hemorrhage Control
From Battlefield Trauma to Civilian Emergency Medicine, Surgery, and Disaster Response
Evidence-Based Scientific Review (2026 Update)
DrRamonReyesMD ⚕️
EMS Solutions International
Abstract
Uncontrolled hemorrhage remains one of the leading preventable causes of death following traumatic injury worldwide. Despite remarkable advances in tourniquets, topical hemostatic dressings, damage control surgery, and resuscitation strategies, rapid hemorrhage control in deep, irregular, or non-compressible wounds continues to represent a major clinical challenge.
Researchers from the Korea Advanced Institute of Science and Technology (KAIST) have recently developed an innovative ionic gelation hemostatic powder (AGCL) capable of transforming into a highly adhesive hydrogel approximately one second after contacting blood through calcium-mediated ionic crosslinking. In preclinical investigations, AGCL demonstrated rapid hemostasis, remarkable blood absorption, strong tissue adhesion, antibacterial activity, accelerated wound healing, and superior performance compared with selected commercially available topical hemostatic products. However, despite these promising findings, clinical trials in humans have not yet been completed, and the technology should still be considered investigational.
Introduction
Hemorrhage accounts for approximately one-third of trauma-related deaths worldwide and represents the single largest preventable cause of mortality following severe injury. Survival frequently depends on achieving effective bleeding control within minutes after injury.
Modern hemorrhage control has evolved dramatically through the implementation of:
- Tactical Combat Casualty Care (TCCC)
- Tactical Emergency Casualty Care (TECC)
- Stop the Bleed®
- Damage Control Resuscitation (DCR)
- Damage Control Surgery (DCS)
Nevertheless, currently available hemostatic agents still present important limitations when treating penetrating injuries, blast wounds, cavitary bleeding, or irregular tissue defects. Conventional gauzes may fail to conform adequately to complex wound geometries, reducing their effectiveness.
These limitations have stimulated the development of next-generation biomaterials capable of rapidly adapting to virtually any wound morphology while simultaneously promoting coagulation and tissue regeneration. AGCL represents one of the most promising examples of this new generation of intelligent hemostatic biomaterials.
The Need for Next-Generation Hemostatic Materials
An ideal topical hemostatic agent should possess several characteristics:
- Rapid deployment
- Easy application
- Strong wet-tissue adhesion
- High mechanical stability
- Excellent biocompatibility
- Broad antimicrobial activity
- Long shelf life
- No refrigeration requirements
- Ability to conform to irregular wounds
- Promotion of wound healing
Many currently available products satisfy some—but not all—of these requirements.
What Is AGCL?
AGCL is an acronym describing a composite powder composed of four principal biomaterials:
- Alginate
- Gellan gum
- Chitosan
- Glutaraldehyde crosslinker
These naturally derived polymers are chemically cross-linked into a three-dimensional network, freeze-dried, mechanically milled, and sieved into a stable powder formulation.
Unlike conventional hydrogel dressings, AGCL is stored as a dry powder and becomes activated only after exposure to blood.
Mechanism of Action
The innovation lies in its ionic gelation mechanism.
Upon contacting blood, physiological calcium ions immediately trigger rapid cross-linking of the gellan gum and alginate polymers.
Within approximately one second, the powder transforms into a highly adhesive hydrogel capable of:
- sealing the bleeding surface;
- conforming to complex wound geometries;
- absorbing large volumes of blood;
- creating a mechanical barrier;
- stabilizing the clot;
- protecting the wound from contamination.
Unlike many conventional powders that primarily concentrate clotting factors by dehydration, AGCL actively constructs a mechanically stable hydrogel scaffold over the injured tissue.
Physicochemical Characteristics
Laboratory characterization demonstrated several remarkable properties:
- Gelation time: ≈1 second
- Blood absorption capacity: ≈725% of its own weight
- Bioadhesion strength: >40 kPa
- Hemolysis: <3%
- Antibacterial efficacy: >99%
- Ambient storage stability: up to 24 months
These characteristics make AGCL particularly attractive for austere environments, military operations, emergency medical services, and disaster medicine where refrigeration and sophisticated logistics may be unavailable.
Biological Performance
Experimental investigations demonstrated that AGCL:
- significantly reduced bleeding time;
- decreased total blood loss;
- promoted faster re-epithelialization;
- stimulated angiogenesis;
- enhanced collagen deposition;
- showed excellent cytocompatibility;
- produced no significant systemic toxicity in animal models.
These findings suggest that AGCL functions not merely as a hemostatic agent but also as a regenerative wound-healing biomaterial.
Potential Clinical Applications
If future human clinical trials confirm its safety and effectiveness, AGCL could have major implications in:
- Military medicine
- Tactical Combat Casualty Care (TCCC)
- Tactical Emergency Casualty Care (TECC)
- Emergency Medical Services (EMS)
- Air medical transport
- Rural and remote medicine
- Damage control surgery
- Emergency departments
- Mass casualty incidents
- Humanitarian missions
- Austere medicine
- Disaster response
Its powder formulation is particularly attractive for treating deep, narrow, and irregular wounds that are difficult to pack using conventional gauze.
Current Limitations
Despite its outstanding preclinical performance, several limitations remain:
- No completed human clinical trials.
- Regulatory approval has not yet been granted.
- Long-term human safety remains unknown.
- Comparative effectiveness against multiple commercial hemostatic agents requires further investigation.
- Performance under anticoagulation, hypothermia, coagulopathy, and severe battlefield conditions still needs evaluation.
Consequently, AGCL should currently be regarded as a highly promising investigational technology rather than an established standard of care.
Conclusion
The development of AGCL represents one of the most significant recent advances in topical hemorrhage control. By combining ultrafast calcium-triggered ionic gelation, exceptional tissue adhesion, high blood absorption, antibacterial properties, prolonged shelf stability, and regenerative potential, this biomaterial addresses several limitations of current hemostatic technologies.
Although additional clinical evidence is still required before widespread implementation, AGCL illustrates the direction in which modern trauma care is evolving: intelligent biomaterials capable of simultaneously controlling hemorrhage, protecting injured tissue, and actively promoting healing.
Should future clinical trials reproduce the impressive results observed in experimental models, AGCL may become an important component of next-generation trauma management across civilian emergency medicine, military medicine, surgery, and disaster response.
Key References
-
Youngju Son, Kyusoon Pak, Taehoon Lee, et al. An Ionic Gelation Powder for Ultrafast Hemostasis and Accelerated Wound Healing. Advanced Functional Materials. 2026;36:e23910. DOI: 10.1002/adfm.202523910.
-
KAIST Research Repository. An Ionic Gelation Powder for Ultrafast Hemostasis and Accelerated Wound Healing.
-
Advanced Functional Materials. First published online October 28, 2025.
No comments:
Post a Comment